Anika Therapeutics (ANIK) Capital Expenditures Growth (1y) (2011 - 2026)
Anika Therapeutics (ANIK) Capital Expenditures Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 8.33% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -19.86% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -1.95% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 73.63% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -0.19% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | -37.60% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -42.11% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Anika Therapeutics | 290.13 Mn | 251.72 Mn | 21.24 Mn | -1.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.23% |
| Mar 31, 2026 | -49.33% |
| Dec 31, 2025 | -50.42% |
| Sep 30, 2025 | 55.18% |
| Jun 30, 2025 | -56.89% |
| Mar 31, 2025 | 56.19% |
| Dec 31, 2024 | -28.97% |
| Sep 30, 2024 | 64.10% |
| Jun 30, 2024 | 133.56% |
| Mar 31, 2024 | 30.17% |
| Dec 31, 2023 | -27.24% |
| Sep 30, 2023 | -56.18% |
| Jun 30, 2023 | -24.90% |
| Mar 31, 2023 | 4.75% |
| Dec 31, 2022 | 124.40% |
| Sep 30, 2022 | 31.70% |
| Jun 30, 2022 | -10.27% |
| Mar 31, 2022 | 132.63% |
| Dec 31, 2021 | 151.00% |
| Sep 30, 2021 | 373.80% |